Health Care • Biotechnology: Pharmaceutical Preparations
$5.94 ▲ +0.00
(0.00%)
MKT CAP: $272.6M • VOL: 845.3K
52W L $5 52W H $26
BIOA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $9.0M | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$92.8M | -$78.2M | -$48.4M |
| Operating Margin % | -80.0% | — | — |
| Net Income (GAAP) | -$80.6M | -$71.1M | -$63.9M |
| EBITDA (Normalized) | -$92.2M | -$77.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$81.6M | -$51.5M | -$37.4M |
| Capital Expenditures (CapEx) | $719.0K | $366.0K | — |
| Free Cash Flow (FCF) | -$82.3M | -$51.9M | -$37.4M |
| FCF Margin % | -80.0% | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $188.9M | $354.3M | — |
| Total Debt (Short + Long Term) | $0 | $2.5M | — |
| Total Stockholders' Equity | $272.1M | $323.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BIOA.